Navigation Links
Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients

Maxygen, Inc. today announced that it has initiated a phase IIa trial to evaluate the efficacy, safety and tolerability of MAXY-G34 in the treatment of chemotherapy-induced neutropenia . MAXY-G34 is a novel pegylated granulocyte colony stimulating factor (PEG-GCSF) shown in preclinical and Phase I studies to have novel and potentially superior properties compared to the current PEG- GCSF therapy.

"Patients and physicians have limited options for treatment of neutropenia," said Russell Howard, chief executive officer of Maxygen. "With MAXY-G34, we hope to expand those options and improve the outcome for many chemotherapy patients. During this first Phase II trial we will begin to learn more about how our drug might play a role in the large, undifferentiated GCSF market."

The Phase IIa trial, which will be conducted at multiple centers in Eastern Europe, is the first trial of MAXY-G34 in patients. Approximately 30 patients with Stage I-III breast cancer will undergo TAC (docetaxel, adriamycin and cyclophosphamide) chemotherapy followed by next-day administration of either MAXY-G34 or Neulasta (control population). The trial is designed as a multiple ascending dose study, with planned doses at 10, 30, 60, or 100 micrograms per kilogram of MAXY-G34 compared to 6mg of Neulasta. Both MAXY-G34 and Neulasta will be administered as a single subcutaneous injection once per chemotherapy cycle.

The primary objective of the Phase IIa trial is to identify one or more doses of MAXY-G34 that effectively treat chemotherapy-induced neutropenia. Patient tolerability, safety, and immunogenicity will be monitored and assessed. Data will also be collected on the pharmacokinetic properties of MAXY-G34 and the mobilization of CD34+ stem cells.

Phase I Results

A Phase I trial was previously conducted to assess the safety and tolerability of MAXY-G34 in 40 healthy volunteers. This study showed MAXY-G34 to be a potent , long-lasting stimulator of neutrophils and an efficient mobilizer of CD34+ stem cells. The drug exhibited a median half-life approximately 2.3 times that of Neulasta. No serious adverse events were reported, and there were no dose-limiting toxicities. No binding or neutralizing antibodies were found at any dose level, with dose levels ranging from 10 - 150 micrograms per kilogram.


'"/>




Related medicine news :

1. Bird Flu: Orissa Initiates Protective Measures
2. Biota Initiates Drug Testing War against Common Cold
3. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
4. Government Initiates A Program To Curb HIV
5. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
6. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
7. SARS-Free Taiwan to Mark End Phase of Global Fight
8. Spray on contraceptive clears Phase I trial
9. Phase 3 trials of two multi-kinase inhibitors against cancer
10. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
11. Phase II trails of new HIV vaccine to be held in South Africa
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/18/2017)... Aliso Viejo, CA (PRWEB) , ... February 18, ... ... styled animating paragraph presets. Use Pixel Film Studios ’ ProParagraph Fashion ... listings, descriptions, and so many other applications. Users can pick and choose ...
(Date:2/17/2017)... Ocala, FL (PRWEB) , ... February 17, 2017 ... ... of software tools that allow for the electronic prescribing of controlled and non-controlled ... , Ninety percent of pharmacies in the United States now accept electronic ...
(Date:2/17/2017)... ... 17, 2017 , ... Qualis Health, one of the nation's ... Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that ... multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... ... 2017 , ... PrideStaff, a national staffing organization, is pleased ... Industry Analysts' 2017 "Staffing 100 North America" list. , Now in its ... the staffing industry over the last twelve months. Industry insiders and observers nominate ...
(Date:2/17/2017)... ... 2017 , ... Dillon Ruxton Insurance, a Florida-based agency offering ... the greater Fort Lauderdale metropolitan region, is embarking on a cooperative food drive ... LifeNet 4 Families has provided a broad range of food provision services to ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... -- DaVita Inc. (NYSE: DVA ) today announced ... Net income attributable to DaVita Inc. for ... million, or $0.80 per share and $880 million, or $4.29 ... to DaVita Inc. for the quarter and year ended December ... million, or $0.98 per share, and $789 million, or $3.85 ...
(Date:2/16/2017)... ST. LOUIS , Feb. 16, 2017  Express Scripts (NASDAQ: ... one of the World,s Most Admired Companies within the Health Care: ... to be named one of the World,s Most Admired Companies," said ... is driven by the commitment and passion of our 26,000 employees ... people we serve." ...
(Date:2/16/2017)... , Feb 16, 2017 Research and Markets ... Diagnostics Market Analysis & Trends - Function, Application, Cancer Type, Technology ... ... Cancer Diagnostics Market is poised to grow at a CAGR of ... by 2025. Some of the prominent trends ...
Breaking Medicine Technology: